{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T21:41:18Z","timestamp":1771623678849,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"DOI":"10.7759\/cureus.100567","type":"journal-article","created":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T15:47:27Z","timestamp":1767282447000},"source":"Crossref","is-referenced-by-count":1,"title":["Beyond Neutropenic Fever: Severe Multiorgan Immune-Related Toxicity Induced by Pembrolizumab"],"prefix":"10.7759","author":[{"given":"Marta","family":"Anast\u00e1cio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiago","family":"Pina Cabral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Rold\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreia","family":"Salgadinho Machado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Lynce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1447021","article-title":"Toxicity in the era of immune checkpoint inhibitor therapy","volume":"15","author":"Keam S","year":"2024","unstructured":"Keam S, Turner N, Kugeratski FG, et al.. Toxicity in the era of immune checkpoint inhibitor therapy. Front Immunol. 2024, 15:1447021. 10.3389\/fimmu.2024.1447021","journal-title":"Front Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00278-X","article-title":"Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study","volume":"25","author":"Wan G","year":"2024","unstructured":"Wan G, Chen W, Khattab S, et al.. Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study. Lancet Oncol. 2024, 25:1053-69. 10.1016\/S1470-2045(24)00278-X","journal-title":"Lancet Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin Q","year":"2023","unstructured":"Yin Q, Wu L, Han L, et al.. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023, 14:1167975. 10.3389\/fimmu.2023.1167975","journal-title":"Front Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-021-00833-8","article-title":"A review of cancer immunotherapy toxicity: immune checkpoint inhibitors","volume":"17","author":"Chhabra N","year":"2021","unstructured":"Chhabra N, Kennedy J. A review of cancer immunotherapy toxicity: immune checkpoint inhibitors. J Med Toxicol. 2021, 17:411-24. 10.1007\/s13181-021-00833-8","journal-title":"J Med Toxicol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.03.012","article-title":"Immune checkpoint inhibitor toxicities","volume":"94","author":"Marin-Acevedo JA","year":"2019","unstructured":"Marin-Acevedo JA, Chirila RM, Dronca RS. Immune checkpoint inhibitor toxicities. Mayo Clin Proc. 2019, 94:1321-9. 10.1016\/j.mayocp.2019.03.012","journal-title":"Mayo Clin Proc"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009016","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"139","author":"Kroll MH","year":"2022","unstructured":"Kroll MH, Rojas-Hernandez C, Yee C. Hematologic complications of immune checkpoint inhibitors. Blood. 2022, 139:3594-604. 10.1182\/blood.2020009016","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60071129","article-title":"Multiorgan toxicity from dual checkpoint inhibitor therapy, resulting in a complete response-a case report","volume":"60","author":"Asta\u0161auskait\u0117 S","year":"2024","unstructured":"Asta\u0161auskait\u0117 S, Kup\u010dinskait\u0117-Noreikien\u0117 R, Zaborien\u0117 I, et al.. Multiorgan toxicity from dual checkpoint inhibitor therapy, resulting in a complete response-a case report. Medicina (Kaunas). 2024, 60:1129. 10.3390\/medicina60071129","journal-title":"Medicina (Kaunas)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye ES","year":"2022","unstructured":"Husebye ES, Castinetti F, Criseno S, et al.. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol. 2022, 187:G1-G21. 10.1530\/EJE-22-0689","journal-title":"Eur J Endocrinol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2023.11.003","article-title":"Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects","volume":"50","author":"Martella S","year":"2023","unstructured":"Martella S, Lucas M, Porcu M, et al.. Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects. Semin Oncol. 2023, 50:144-8. 10.1053\/j.seminoncol.2023.11.003","journal-title":"Semin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2020.100011","article-title":"How we treat endocrine complications of immune checkpoint inhibitors","volume":"6","author":"Paschou SA","year":"2021","unstructured":"Paschou SA, Stefanaki K, Psaltopoulou T, et al.. How we treat endocrine complications of immune checkpoint inhibitors. ESMO Open. 2021, 6:100011. 10.1016\/j.esmoop.2020.100011","journal-title":"ESMO Open"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider B, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018, 36:1714-68.","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-50574-6","article-title":"Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab","volume":"9","author":"Eun Y","year":"2019","unstructured":"Eun Y, Kim IY, Sun JM, et al.. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci Rep. 2019, 9:14039. 10.1038\/s41598-019-50574-6","journal-title":"Sci Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/439674-beyond-neutropenic-fever-severe-multiorgan-immune-related-toxicity-induced-by-pembrolizumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T15:47:27Z","timestamp":1767282447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/439674-beyond-neutropenic-fever-severe-multiorgan-immune-related-toxicity-induced-by-pembrolizumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.100567","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}